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RESUMEN 
 
Se estudiaron pacientes seropositivos para el virus de inmunodeficiencia humana 
tipo 1 (VIH-1) con y sin tratamiento, con el fin de determinar el polimorfismo y la 
prevalencia de mutaciones de resistencia a la terapia antirretroviral. El material genético 
viral fue extraído a partir de células mononucleares de sangre periféricas (ADN) y del 
plasma (ARN) de 30 pacientes. Se amplificaron 2 regiones del gen Pol, Transcriptasa 
Reversa (TR) y Proteasa (Pr) y el gen de envoltura (Env) por medio de la técnica de PCR y 
se obtuvo la secuencia genómica de los productos. Todos los aislados analizados 
pertenecieron al subtipo B. No se observaron mutaciones primarias asociadas a resistencia a 
inhibidores de Pr pero sí un alto porcentaje (86%, 19/22) de mutaciones no asociadas con 
resistencia sino a restitución de la capacidad replicativa de cepas mutantes (mutaciones 
secundarias). Se observó la presencia de mutaciones asociadas a resistencia a inhibidores 
nucleósidos de la TR (INTR) en 35% (6/17) de los pacientes sometidos a tratamiento, 
mientras que 12% (2/17) de ellos presentaron mutaciones de resistencia a inhibidores no 
nucleósidos de la TR (INNTR). Interesantemente, un paciente no tratado estaba infectado 
con una cepa que presentaba mutaciones primarias (7,7%); este resultado sugiere que 
podría ser importante plantearse el estudio local de determinación de resistencia genotípica 
en pacientes antes del tratamiento, con miras a minimizar fallas terapéuticas. Se requieren 
estudios adicionales para evaluar el rol de las mutaciones secundarias en el éxito de la 
infección viral. 
 
 
Palabras  clave:  VIH-1,  Sur  América,  mutaciones  secundarias,  capacidad  replicativa, 
recombinación. 
3 
 
 
 
ABSTRACT 
 
The genetic variability was studied in HIV-1 from Venezuelan patients with and 
without treatment, in order to evaluate the presence of polymorphisms and drug resistance 
mutations. Proviral DNA from peripheral blood mononuclear cells or viral RNA from 
plasma was extracted from the blood of 30 patients. Two regions from the polymerase 
gene, protease (Pr) and reverse transcriptase (RT) and one genomic fragment from the 
envelope (Env) gene were amplified and sequenced. All HIV-1 samples analyzed were 
classified as subtype B, without evidence of recombination. Although no primary protease 
mutations were detected, a high frequency of secondary mutations (86%, 19/22), associated 
to restoration of viral replicative fitness, was observed in strains circulating both in treated 
and non-treated patients. Resistance mutations to nucleoside RT inhibitors (NRTI) and non- 
nucleoside RT inhibitors (NNRTI) were detected in 35% (6/17) and 12% (2/17) of the 
viruses circulating in treated patients, respectively. Resistance mutations were also present 
in the virus infecting one antiretroviral naïve individual (7.7%), suggesting that local 
screening for resistant mutation in naïve patient might be important to minimize therapy 
failure. Future studies are warranted to assess the role of secondary mutation in the success 
of viral infection. 
 
 
 
 
Keywords: HIV-1, South America, Secondary mutations, Fitness, Recombination. 
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INTRODUCTION 
 
Around 39 million persons are infected with human immunodeficiency virus type 1 
(HIV-1) worldwide, and more than 20 millions have already died from this disease (1). In 
Venezuela, at the end of 2003, 110000 (47000-170000) persons were estimated to be 
infected (1). Three groups have been described for HIV-1, M, N and O. HIV-1 group M 
exhibits a worldwide distribution and can be classified into 24 different genetic variants, 
which include at least 11 subtypes (2). Viral mutations also occur during the infection and 
many of them are related to the pressure exerted by the immune system and/or to the 
antiretroviral therapy (3). 
Highly active anti-retroviral therapy (HAART), especially that including triple-drug 
combination, has proved to be beneficial to HIV infected patients. Effective HAART 
induces a sustained reduction of the plasma viral load, an increase in the CD4+ T cells 
counts, and also a delayed disease progression to AIDS. However, such benefits may be 
hampered by important risks associated with prolonged treatment, such as metabolic 
disturbances, pharmacological interactions, and low adherence. Such circumstances can 
lead to the rapid development of viral resistance (4). The susceptibility to a drug of a 
specific viral isolate can be tested phenotypically, by in vitro assay, or genotypically, by 
sequencing and assessment of drug resistance by evaluation through database algorithms 
(5). Additionally, genotypic testing offers the possibility of detecting secondary mutations, 
i.e., mutations which do not confer drug resistance but help in restoring the replication 
ability or fitness of the mutant viruses (3). The aim of this study was to pursue the 
molecular survey of HIV isolates circulating in Venezuela, in order to evaluate the presence 
of polymorphisms and drug resistance mutations. 
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MATERIALS AND METHODS 
 
Patients. A total of 30 HIV-1 positive patients (mean age: 33 years, range: 20-57, 4 women 
and 26 men) were included in this study, upon written consent. Seventeen patients were 
receiving treatment (T) and 13 were either naive or had not received treatment for at least 2 
years (NT). 
PCR. Proviral DNA and/or RNA were extracted from peripheral blood mononuclear cells 
(PBMC) or plasma with commercial kits (QIAamp® DNA Blood mini Kit and QIAamp® 
UltraSens VirusKit, QIAGEN, Germany). Two regions from the polymerase gene, reverse 
transcriptase (RT) and protease (Pr), and one region from envelope gene (Env) were 
amplified by nested PCR or RT-PCR (6). Primers used for Env amplification were: E80 
(5´-ccaattcccatacattattgtg-3´) and E105 (5´-gcttttcctacttcctgccac-3´) for the first round and 
E110 (5´-tgttaaatggcagtctagcagaa-3´) and E125 (5´-caatttctgggtcccctcctgagg-3´) for the 
second round. 
Sequencing. PCR fragments were sequenced using dye terminator labeling method (ABI 
PRISM
TM 
Dye terminator Cycle Sequencing ready reaction Kit; Perkin Elmer; Foster; CA) 
with 377 DNA sequencer (Applied Biosystems, Foster, CA). Both strands of DNA were 
sequenced. Nucleotide alignments and phylogenetic analyses were performed using 
DNAMAN Version 5.2.2. (Lynnon Bio Soft, Canada). Phylogenetic trees were obtained 
using the Neighbor Joining Method (100 bootstrap replications). Genetic distances were 
evaluated with Kimura 2 parameters corrections. Nucleotide sequence data have been 
deposited into the GenBank database under the accession numbers AY841802-AY841853. 
Determination of genotypic resistance. Sequences were submitted to a genotype sequence 
algorithm (Los Alamos Resistance Database: HIVdb: Drug Resistance Algorithm, Beta 
Test, http://hivdb2.stanford.edu/asi/deployed/hiv_central.pl?program=hivdb). Amino acids 
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1 to 99 and 1 to 242 were analyzed for Pr and RT respectively. Statistical significance was 
assessed by the chi square test with Yate's correction, according to a computerized Epi Info 
program, version 5.01b (Centers for Disease Control and Prevention, Atlanta, GA, USA). 
 
 
RESULTS 
 
Nucleic acids were extracted from 30 plasma samples and 21 PBMC to amplify 
products of 805, 515 y 332 nucleotides approximately, corresponding to the regions RT, Pr 
and Env regions, respectively. Amplification was more efficient from proviral DNA and 
similar for all the regions, but for none of the samples amplification was obtained for all the 
regions in the two compartments (data not shown). 
A total of 30 sequences were available for RT region and 22 for Pr region. Sequence 
analysis of the polymerase region, or RT (Figure 1A) and Pr separately, showed that all 
HIV-1 isolates belonged to subtype B. Venezuelan isolates were not grouped either in a 
specific clade, or according to viral load, CD4+ T cell counts, specific mutations and/or 
antiretroviral treatment. Phylogenetic analysis of 22 isolates in the Env region also grouped 
all the Venezuelan isolates inside subtype B, therefore suggesting the absence of 
recombination in these isolates (Figure 1B). Phylogenetic grouping in the Env region was 
not supported by high bootstrap values, probably due to the short length of the region 
analyzed; all the isolates were grouped however inside subtype B clade and exhibited more 
than 78% similarity with subtype B and less than 77% with other subtypes. 
Primary mutations were not observed in the Pr region, being the frequency of Pr 
mutations significantly lower than that recorded for RT mutations (0/22 vs. 7/30, p= 0.02). 
However, the majority of the isolates exhibited secondary mutations (80%, 19/22), being 
the most common one in the amino acid 63 (73%), with L63P found in 56% of the 
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sequences analyzed (Figure 2A). Mutation in such codon was present both in treated and in 
naïve patients, with a similar frequency (7/8 in non treated patients vs. 10/13 in treated 
patients, statistically NS). Primary mutations, conferring resistance to nucleoside RT 
inhibitors (NRTI), were observed in 23% (7/30) of the isolates and mutations conferring 
resistance to non nucleoside RT inhibitors (NNRTI) in 6.7% (2/30) of the isolates (Figures 
2B and 2C). The most common NRTI mutation was V118I, which confers intermediate 
resistance to 3TC when present with E44A/D. Six out of 17 (35%) and 2/17 (12%) of the 
treated patients harbored viral strains with mutations conferring resistance to NRTI and 
NNRTI respectively. One untreated patient (1/13, 7.7%) harbored and HIV-1 isolate with 
multiple NRTI mutations: this individual referred sexual contact with a partner receiving 
HAART. 
 
 
DISCUSSION 
 
Previous studies suggest that plasma is the compartment most commonly used for 
assessing genotypic resistance. Although plasma better reflects the viral quasispecies 
circulating at a given moment in the host, and most recently selected by antiretroviral 
pressure, other studies have shown that the proviral DNA determination may allow for the 
detection of other mutations, not expressed at the moment of the testing; therefore, more 
suitable to test the potential of drug resistance in the strain infecting a particular host (7, 8). 
The choice of the most suitable compartment to assess genotypic resistance is still an open 
issue (9). An alternative approach would be to study several body compartments, 
particularly when the genotypic analysis of the viral strain does not explain the viral 
relapse. In general, there seems to be a good correlation between the genotypic variability 
observed in the proviral DNA and in the plasma viral RNA (10). In our study, most of the 
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genomic  sequences  were  derived  from  proviral  DNA,  due  to  the  higher  efficiency  of 
amplification in this compartment. 
Phylogenetic analysis showed that subtype B is still highly predominant in 
Venezuela, as previously reported (11-15). Nevertheless, recombinant B/F (16), B/C and 
subtype C isolates have been described more recently (17). Recombination in retroviruses 
is a complex phenomenon and can occur many times in a single genome (2), which may 
hamper the identification of recombinant strains. Sequencing of multiple regions of HIV-1 
genome is then a convenient strategy to rule out the presence of recombinant strains (18), 
allowing at the same time for subtype assignment and determination of genotypic 
resistance. The relative low diversity of HIV-1 Venezuelan isolates found in this study and 
in other recent surveys (11; Suarez, JA, personal communication) contrasts with the general 
assumption of an ascending epidemic in this country; more studies are needed to assess the 
actual prevalence of HIV infection in Venezuela and the eventual introduction of other HIV 
variants in specific epidemiological settings. 
In our series, primary mutations to RT inhibitors were found mainly in patients 
receiving the specific drug for which the strain developed resistance, although one naive 
patient harbored a drug resistant isolate. Whereas the number of naive patients analyzed is 
low, similar results have been found by others in Venezuela (11), suggesting the circulation 
of resistant strains among naive patients in such a frequency that might justify the 
determination of genotypic resistance test before the initiation of treatment. K103N 
substitution, which was found in association with the NRTI V118I mutation in one treated 
patient, is a mutation confering high level resistance to current NNRTI (19). This mutation 
has been found to persist after single dose administration of nevirapine (NVP) and might 
not reduce the fitness of the mutant virus (20, 21). On the other hand, no primary mutations 
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were observed in half of the patients (4/8) with suspicion of relapse. In these patients, 
viremia rebound might be due to non-adherence to antiretroviral treatment rather than 
virological failure. 
Although rather infrequent, Y318F mutation confers resistance to delavirdine 
(DLV) and low level resistance to NVP (21). Amino acids 318 and 333 were not analyzed 
in this study. Nevertheless, it must be emphasized that some commercial genotyping assays 
do not analyze these amino acids either. 
The absence of primary mutations in the Pr region observed in our study is 
consistent with what has been already found by others in Venezuela (11), and might be 
influenced by the low number of samples analyzed for Pr mutations. On the other hand, a 
relatively high frequency of secondary mutations, not necessarily associated with HAART, 
was found in this protein, particularly L63P mutation. Such mutations may contribute to a 
rapid evolution of the resistance strain selected under Pr inhibitor pressure (22). The role of 
these secondary mutations in the replicative fitness of wild-type viruses deserves further 
clarification. 
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LEGENDS 
 
 
 
Figure 1: Phylogenetic analysis of RT (A) and Env (B) regions. Sequences obtained in this 
study are displayed in bold, with an R in the case of exhibiting resistance. Isolates are designated 
by their GenBank accession number and the name of the country of origin for subtype B 
sequences, except for Venezuelan isolates, which are shown in bold, with an R in the case of 
exhibiting resistance. Bootstrap values over 80% are shown in the tree. The scale represents the 
number of substitutions/site/100 bases. Letters in bold in the tree indicate subtype. 
 
 
Figure 2: Frequency of mutations associated to resistance to Pr, NRTI and NNRTI. 
 
: Primary mutations. : Secondary mutations. : Absence of mutations. : 
K238T is a NNRTI-selected mutation that usually occurs in combination with other NNRTI- 
resistance mutations and which appears to confer intermediate levels of resistance to NVP and 
possibly DLV and efavirenz (EFV). In this HIV-1 isolate, the mutation was not found in 
combination with another NNRT resistance mutation. 
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